Instruction for use: Reaferon-EC

Dosage form: Lyophilizate for solution for injection and topical application

Active substance: Interferonum alpha-2b

ATX

L03AB04 Interferon alfa-2a

Pharmacological groups:

Antiviral drugs (excluding HIV)

Interferons

The nosological classification (ICD-10)

A39 Meningococcal infection: Asymptomatic carriage of meningococci; Infection of meningococcal; Meningococcus aureus; The epidemic of meningitis

A49.3 Mycoplasma infection, unspecified: Mycoplasma infection; Urogenital mycoplasmosis; Pulmonary infection caused by mycoplasma; Mycoplasma infections; Mycoplasmosis; Genitourinary infection caused by mycoplasma; Mycoplasma meningoencephalitis

A86 Viral encephalitis, unspecified: Viral encephalitis; Enterovirus meningoencephalitis; Encephalitis of viral etiology; Encephalomyelitis of viral etiology

A87 Viral meningitis

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

B18.1 Chronic viral hepatitis B without delta-agent: Chronic viral hepatitis B; Chronic active hepatitis B; Chronic viral hepatitis B; Chronic hepatitis B; Chronic hepatitis B HBeAg-negative

B18.2 Chronic viral hepatitis C: Hepatitis C; Recurrence of chronic hepatitis C; Chronic active hepatitis C; Chronic viral hepatitis C; Chronic hepatitis C without cirrhosis; Chronic hepatitis C

B30 Viral conjunctivitis

C44 Other malignant neoplasms of the skin: Malignant skin tumors; Basalioma; Basaliomas; Basal cell epithelioma; Basal cell carcinoma; Basal cell carcinoma of the skin; Basal cell carcinoma of the skin; Malignant reticulosis; Ulcerated basal cell; Skin Cancer; Skin carcinoid; Skin Lymphoma; Primary reticulosis; Primary skin reticulosis; Squamous cell carcinoma; Squamous cell carcinoma of the skin; Superficial skin tumors; Skin cancer; Reticulosis of the skin; Skin Reticulosarcoma; Sarcomatosis of the skin; Skin cancer (endophytic forms of I and II stages); Squamous cell carcinoma and basal cell carcinoma

C46 Kaposi's sarcoma: Kaposi angioreticulosis; Endotheliosarcoma; Kaposi angiosarcomatosis; Kaposi hemangiosarcoma; Kaposi haemorrhagic sarcoma; Kaposi multiple hemorrhagic sarcoma; Kaposi telangiectatic pseudo-sarcoma; Kaposi's Sarcoma in AIDS patients; Varioleiform pustulosis of Kaposi; Kaposi's Sarcoma in AIDS; Kaposi's sarcoma on AIDS; Kaposi's sarcoma on the background of AIDS; AIDS-associated Kaposi's sarcoma

C64 Malignant neoplasm of kidney, other than renal pelvis: Wilms tumor; Kidney Cancer; Metastatic Renal Cell Carcinoma; Renal carcinoma; Inoperable kidney carcinomas; Metastatic kidney carcinoma; Metastatic Renal Cell Carcinoma; Wilms tumor; Wilms swelling; Adenomyosarcoma; Adenomyocystosarcoma; Adenosarcoma of the kidney; Kidney Cancer; Common renal cell carcinoma; Nephroblastoma; Nephroma; Embryonal nephroma; Recurrent carcinoma of the kidney; Birch-Hirschfeld Tumor; Common renal cell carcinoma; Tumors of the kidney

C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues: Hematoblastosis; Hematosarcoma; Leukemia; Lymphoma of the malignant; Tumors of lymphoid, hematopoietic and related tissues

C91.0 Acute lymphoblastic leukemia: Recurrence of acute leukemia; Blast Crisis; Blest Crisis; Lymphoblastic leukemia; Lymphoid blast crisis; Acute lymphoblastic leukemia; Acute lymphoblastic leukemia in adults and children; Acute lymphoblastic leukemia in children; Acute lymphatic leukemia

C91.4 Hairy-cell leucosis

G04 Encephalitis, myelitis and encephalomyelitis: Disseminated acute encephalomyelitis; Leukoencephalitis; Meningomielitis; Myelitis; Acute encephalitis; Acute encephalomyelitis; Chronic encephalitis; Chronic encephalomyelitis; Encephalitis; Encephalomyelitis; Inflammation of meninges

G35 Multiple Sclerosis: Disseminated Sclerosis; Multiple sclerosis; Recurrent multiple sclerosis; Secondary-progressive multiple sclerosis; Exacerbation of multiple sclerosis; Mixed forms of multiple sclerosis

Composition and release form

1 ampoule with dry substance for injection contains interferon alfa-2b 0.5; 1; 3 or 5 million IU, not more than 5 mg of donor albumin and 9.5 mg of sodium chloride; In packs of 10 pcs. With an ampoule knife or scarifier or in a contour acheikova pack 5 or 10 pcs.

Pharmachologic effect

Mode of action - antiviral, immunomodulating, antitumor.

Indication of the Reaferon-ÅÑ

Viral hepatitis B, C, D, viral, viral-bacterial and mycoplasma meningoencephalitis, viral conjunctivitis, keratoconjunctivitis, keratitis, keratouveitis, stage IV kidney cancer, hairy cell leukemia, malignant skin lymphomas, Kaposi's sarcoma, skin cancer (basal cell and squamous cell), keratoacanthoma , Multiple sclerosis, lymphoblastic leukemia in children, respiratory papillomatosis of the larynx.

Contraindications

Hypersensitivity.

Application in pregnancy and breastfeeding

Contraindicated.

Side effects

Increased temperature, chills, leuko- and thrombocytopenia, skin allergic reactions

Dosing and Administration

IM (in the outbreak or under the lesion), subconjunctival, local. Acute hepatitis B - 1 million IU IM / m 2 times per day for 5-6 days (course - 15 million IU); Chronic active hepatitis B - 1 million IU IM / m 2 times per week for 1-2 months; Chronic active hepatitis B and D (with signs of cirrhosis of the liver) - 250-500 thousand IU per day v / m 2 times a week for 1 month; Hairy cell leukemia - 3-6 million IU daily for 2 months, (course - 420-600 million IU); Kidney cancer - 3 million IU daily for 10 days (course - 120-300 million IU); Stromal keratitis and keratoiridocyclitis - subconjunctival for 60 thousand IU in a volume of 0.5 ml daily (course - 15-25 injections).

Special instructions

Contains no more than 5 mg of albumin from the blood of a donor who underwent a control for the absence of HBs-antigen and antibodies to HIV.

Storage conditions of the drug Reaferon-ÅÑ

In the dark place at a temperature of no higher than 8 ° C.

Keep out of the reach of children.

Shelf life of the drug Reaferon-ÅÑ

3 years.

Do not use after the expiry date printed on the package.